A Study of MabThera/Rituxan (Rituximab) Alone and in Comb... | NCT01609010

Status Module

Name	Class
Nordic Lymphoma Group	NETWORK

Description Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Rituximab Monotherapy	Active Comparator	Participants received 375 milligrams per square meter (mg/m2) rituximab intravenously (i.v.) weekly for 4 weeks. Participants achieving minor response (MR), partial response (PR), or completer response (CR) received a second cycle of treatment.	Drug: rituximab
Rituximab, Interferon	Experimental	Participants received 375 mg/m2 rituximab i.v. weekly for 4 weeks; and 3 million international units per day (MIU/day) interferon-a2a subcutaneously (s.c.) during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5. Interferon-a2a was not administered on days of rituximab administration. Participants achieving MR, PR, or CR received a second cycle of treatment.	Drug: rituximab Drug: interferon-a-2a

Name	Type	Description	Arm Group Labels	Other Names
rituximab	Drug	375 mg/m2 rituximab i.v. weekly for 4 weeks	Rituximab Monotherapy Rituximab, Interferon

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Treatment Failure - Percentage of Participants With an Event	Treatment failure was defined as an event of any of the following: progressive disease while receiving study treatment, death due to any cause, or the initiation of another type of treatment due to stable disease, progressive disease or relapse, or intolerance to study treatment.	Baseline (BL), Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period
Treatment Failure - Time to Event	The median time, in months, between randomization and treatment failure event determined using Kaplan-Meier estimates.	BL, Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period

Secondary Outcomes

Measure	Description	Time Frame
Percentage of Participants Achieving Complete Response (CR), Unconfirmed CR (CRu), or Partial Response (PR)	CR was defined as the complete disappearance of all previously detectable disease signs; the absence of palpable lymph nodes greater than (>) 1 centimeter (cm) or nodes >1.5 cm observed in computerized axial tomography (CAT) scan; and negative bone marrow pathology, if initially positive. CRu was defined as CR, except that bone marrow results were indeterminate. PR was defined as a decrease of greater than or equal to (≥) 50 percent (%) compared with the BL value in the sum of the products of the two largest perpendicular diameters in all measurable and evaluable lesions; and a ≥50% reduction of the size from BL if hepato-splenomegaly was present.

Eligibility Module

Name	Affiliation	Role
Clinical Trials	Hoffmann-La Roche	Study Chair

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
25686644	Derived	Kimby E, Ostenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundstrom C; Nordic Lymphoma Group (NLG). Two courses of four weekly infusions of rituximab with or without interferon-alpha2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leuk Lymphoma. 2015;56(9):2598-607. doi: 10.3109/10428194.2015.1014363. Epub 2015 Mar 11.

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Rituximab Monotherapy	Participants rituximab received 375 milligrams per square meter (mg/m^2), intravenously (IV), once weekly for 4 weeks. Participants who achieved minor response (MR), partial response (PR), or complete response (CR) after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
FG001

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Arm/Group Information

ID	Title	Description
BG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
BG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.
BG002	Total	Total of all reporting groups

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Treatment Failure - Percentage of Participants With an Event

Treatment failure was defined as an event of any of the following: progressive disease while receiving study treatment, death due to any cause, or the initiation of another type of treatment due to stable disease, progressive disease or relapse, or intolerance to study treatment.

ITT population

Posted

Number

percentage of participants

Baseline (BL), Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period

ID	Title	Description
OG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
OG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.

Units	Counts
Participants	OG000156 OG001157

Title

Denominators

Categories

Title	Measurements
	OG00068 OG00167

Primary

Treatment Failure - Time to Event

The median time, in months, between randomization and treatment failure event determined using Kaplan-Meier estimates.

ITT population

Posted

Median

95% Confidence Interval

months

BL, Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period

ID	Title	Description
OG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
OG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.

Units	Counts
Participants

Secondary

Percentage of Participants Achieving Complete Response (CR), Unconfirmed CR (CRu), or Partial Response (PR)

CR was defined as the complete disappearance of all previously detectable disease signs; the absence of palpable lymph nodes greater than (>) 1 centimeter (cm) or nodes >1.5 cm observed in computerized axial tomography (CAT) scan; and negative bone marrow pathology, if initially positive. CRu was defined as CR, except that bone marrow results were indeterminate. PR was defined as a decrease of greater than or equal to (≥) 50 percent (%) compared with the BL value in the sum of the products of the two largest perpendicular diameters in all measurable and evaluable lesions; and a ≥50% reduction of the size from BL if hepato-splenomegaly was present.

ITT population; number (n) equals (=) number of participants assessed for the specified parameter at a given visit.

Posted

Number

95% Confidence Interval

percentage of participants

Weeks 10 and 16

ID	Title	Description
OG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
OG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.

Secondary

Percentage of Participants Achieving CR or CRu

CR was defined as the complete disappearance of all previously detectable disease signs; the absence of palpable lymph nodes >1 cm or nodes >1.5 cm observed in CATscan; and negative bone marrow pathology, if initially positive. CRu was defined as CR, except that bone marrow results were indeterminate.

ITT population; n=number of participants assessed for the specified parameter at a given visit.

Posted

Number

95% Confidence Interval

percentage of participants

Weeks 10 and 16

ID	Title	Description
OG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
OG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.

Secondary

Duration of Response - Percentage of Participants With an Event

Response duration was defined as the period between the date for first observation of CR, CRu or PR and the date of progressive disease (PD), censored observation or death of any cause. Response duration was also assessed for response defined as CR only. Response duration was calculated among responders (CR+CRu+PR) with cutoffs for follow-up applied.

ITT population

Posted

Number

percentage of participants

BL, Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period

ID	Title	Description
OG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
OG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.

Secondary

Duration of Response

The median time, in months, from the date of the first observation of CR, CRu, or PR and the date of progressive disease (PD), censored observation, or death due to any cause. PD was defined as an increase of >50% compared to BL in the sum of the product of the two largest perpendicular parameters of measurable lymphoma, or the occurrence of new lesions. One month=30.4 days. Response duration was calculated amongst responders (CR+CRu+PR) with cutoffs for follow-up applied.

ITT population; n=number of participants assessed for the specified parameter at a given visit. Only participants with a response (CR+CRu+PR, CR+CRu, or CR only) were included in the analysis.

Posted

Median

95% Confidence Interval

months

BL, Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period

ID	Title	Description
OG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
OG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.

Secondary

Disease Progression - Percentage of Participants With an Event

A disease progression event was defined as tumor progression or death due to any cause (or a censored observation).

ITT population

Posted

Number

percentage of participants

BL, Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period

ID	Title	Description
OG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
OG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.

Units	Counts
Participants

Secondary

Time to Disease Progression

The median time, in months, from randomization to disease progression event assessed using Kaplan-Meier estimates. One month=30.4 days

ITT population

Posted

Median

95% Confidence Interval

months

BL, Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period

ID	Title	Description
OG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
OG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.

Units	Counts
Participants

Secondary

Overall Survival (OS) - Percentage of Participants With an Event

An overall survival event was defined as death due to any cause.

ITT population

Posted

Number

percentage of participants

BL, Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period

ID	Title	Description
OG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
OG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.

Units	Counts
Participants

Secondary

Overall Survival

The median time, in months, from randomization to OS event assessed using Kaplan-Meier estimates. One month=30.4 days

ITT population

Posted

Median

Full Range

months

BL, Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period

ID	Title	Description
OG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.
OG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.

Units	Counts
Participants

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Rituximab Monotherapy	Participants rituximab received 375 mg/m^2, IV, once weekly for 4 weeks. Participants who achieved MR, PR, or CR after the first cycle received a second cycle of treatment for a maximum of 2 cycles.			13	156	138	156
EG001	Rituximab + IFN	Participants received rituximab 375 mg/m^2, IV, once weekly for 4 weeks. Participants also received IFN-α2a 3 MIU/day, SC, during Week 1, and 4.5 MIU/day, SC, 6 days per week during Weeks 2 through 5. IFN-α2a was not administered on days of rituximab administration. Participants who achieved MR, PR, or CR during the first cycle received a second cycle of treatment for a maximum of 2 cycles.			34	157	155	157

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
General disorders and administration site conditions (ASC)	General disorders	MedDRA 14	Non-systematic Assessment	EG0002 affected156 at risk EG0019 affected157 at risk
Gastrointestinal disorders	Gastrointestinal disorders	MedDRA 14.0	Non-systematic Assessment	EG0004 affected156 at risk EG0016 affected157 at risk
Blood and lymphatic system disorders	Blood and lymphatic system disorders	MedDRA 14.0	Non-systematic Assessment	EG0001 affected156 at risk EG0016 affected157 at risk
Respiratory, thoracic and mediastinal (T&M) disorders	Respiratory, thoracic and mediastinal disorders	MedDRA 14.0	Non-systematic Assessment	EG0001 affected156 at risk EG0012 affected157 at risk
Infections and infestations	Infections and infestations	MedDRA 14.0	Non-systematic Assessment	EG0003 affected156 at risk EG0015 affected157 at risk
Nervous system disorders	Nervous system disorders	MedDRA 14.0	Non-systematic Assessment	EG0001 affected156 at risk EG0014 affected157 at risk
Musculoskeletal and connective tissue (CT) disorders	Musculoskeletal and connective tissue disorders	MedDRA 14.0	Non-systematic Assessment	EG0001 affected156 at risk EG0012 affected157 at risk
Immune system disorders	Immune system disorders	MedDRA 14.0	Non-systematic Assessment	EG0001 affected156 at risk EG0011 affected157 at risk
Investigations	Investigations	MedDRA 14.0	Non-systematic Assessment	EG0000 affected156 at risk EG0011 affected157 at risk
Cardiac disorders	Cardiac disorders	MedDRA 14.0	Non-systematic Assessment	EG0001 affected156 at risk EG0012 affected157 at risk
Injury, poisoning and procedural complications (PC)	Injury, poisoning and procedural complications	MedDRA 14.0	Non-systematic Assessment	EG0000 affected156 at risk EG0013 affected157 at risk
Metabolism and nutrition disorders	Metabolism and nutrition disorders	MedDRA 14.0	Non-systematic Assessment	EG0000 affected156 at risk EG0012 affected157 at risk
Skin and subcutaneous tissue disorders	Skin and subcutaneous tissue disorders	MedDRA 14.0	Non-systematic Assessment	EG0000 affected156 at risk EG0011 affected157 at risk
Psychiatric disorders	Psychiatric disorders	MedDRA 14.0	Non-systematic Assessment	EG0000 affected156 at risk EG0011 affected157 at risk
Vascular disorders	Vascular disorders	MedDRA 14.0	Non-systematic Assessment	EG0001 affected156 at risk EG0010 affected157 at risk
Ear and labyrinth disorders	Ear and labyrinth disorders	MedDRA 14.0	Non-systematic Assessment	EG0000 affected156 at risk EG0011 affected157 at risk
Eye disorders	Eye disorders	MedDRA 14.0	Non-systematic Assessment	EG0000 affected156 at risk EG0011 affected157 at risk
Neoplasms benign, malignant and unspecified (including cysts)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 14.0	Non-systematic Assessment	EG0001 affected156 at risk EG0010 affected157 at risk

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
General disorders and ASC	General disorders	MedDRA 14	Non-systematic Assessment	EG00070 affected156 at risk EG001141 affected157 at risk
Gastrointestinal disorders	Gastrointestinal disorders	MedDRA 14.0	Non-systematic Assessment	EG00048 affected156 at risk EG001101 affected157 at risk
Musculoskeletal and connective tissue disorders	Musculoskeletal and connective tissue disorders	MedDRA 14	Non-systematic Assessment	EG00035 affected156 at risk EG00181 affected157 at risk
Nervous system disorders	Nervous system disorders	MedDRA 14.0	Non-systematic Assessment	EG00022 affected156 at risk EG00182 affected157 at risk
Infections and infestations	Infections and infestations	MedDRA 14.0	Non-systematic Assessment	EG00038 affected156 at risk EG00158 affected157 at risk
Skin and subcutaneous tissue disorders	Skin and subcutaneous tissue disorders	MedDRA 14.0	Non-systematic Assessment	EG00029 affected156 at risk EG00165 affected157 at risk
Respiratory, T&M disorders	Respiratory, thoracic and mediastinal disorders	MedDRA 14.0	Non-systematic Assessment	EG00037 affected156 at risk EG00132 affected157 at risk
Psychiatric disorders	Psychiatric disorders	MedDRA 14.0	Non-systematic Assessment	EG00011 affected156 at risk EG00138 affected157 at risk
Vascular disorders	Vascular disorders	MedDRA 14.0	Non-systematic Assessment	EG00021 affected156 at risk EG00116 affected157 at risk
Immune system disorders	Immune system disorders	MedDRA 14.0	Non-systematic Assessment	EG00015 affected156 at risk EG00118 affected157 at risk
Blood and lymphatic system disorders	Blood and lymphatic system disorders	MedDRA 14.0	Non-systematic Assessment	EG0006 affected156 at risk EG00120 affected157 at risk
Metabolism and nutrition disorders	Metabolism and nutrition disorders	MedDRA 14.0	Non-systematic Assessment	EG0002 affected156 at risk EG00123 affected157 at risk
Investigations	Investigations	MedDRA 14.0	Non-systematic Assessment	EG0006 affected156 at risk EG00114 affected157 at risk
Eye disorders	Eye disorders	MedDRA 14.0	Non-systematic Assessment	EG0003 affected156 at risk EG00116 affected157 at risk
Cardiac disorders	Cardiac disorders	MedDRA 14.0	Non-systematic Assessment	EG0007 affected156 at risk EG0019 affected157 at risk
Injury, poisoning and procedural complications	Injury, poisoning and procedural complications	MedDRA 14.0	Non-systematic Assessment	EG0004 affected156 at risk EG0018 affected157 at risk
Reproductive system and breast disorders	Reproductive system and breast disorders	MedDRA 14.0	Non-systematic Assessment	EG0001 affected156 at risk EG00111 affected157 at risk
Ear and labyrinth disorders	Ear and labyrinth disorders	MedDRA 14.0	Non-systematic Assessment	EG0000 affected156 at risk EG0017 affected157 at risk
Renal and urinary disorders	Renal and urinary disorders	MedDRA 14.0	Non-systematic Assessment	EG0005 affected156 at risk EG0012 affected157 at risk
Neoplasms benign, malignant and unspecified (including cysts)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 14.0	Non-systematic Assessment	EG0004 affected156 at risk EG0010 affected157 at risk
Surgical and medical procedures	Surgical and medical procedures	MedDRA 14.0	Non-systematic Assessment	EG0001 affected156 at risk EG0010 affected157 at risk

Facility	Status	City	State	ZIP	Country	Contacts
		Copenhagen		2100	Denmark

ID	Term
D009370	Neoplasms by Histologic Type
D009369	Neoplasms
D008232	Lymphoproliferative Disorders
D008206	Lymphatic Diseases
D006425	Hemic and Lymphatic Diseases
D007160	Immunoproliferative Disorders
D007154	Immune System Diseases

ID	Term
D058846	Antibodies, Monoclonal, Murine-Derived
D000911	Antibodies, Monoclonal
D000906	Antibodies
D007136	Immunoglobulins
D007162	Immunoproteins
D001798	Blood Proteins
D011506	Proteins
D000602	Amino Acids, Peptides, and Proteins
D012712	Serum Globulins
D005916	Globulins
D016898	Interferon-alpha
D007370	Interferon Type I
D007372	Interferons
D016207	Cytokines
D036341	Intercellular Signaling Peptides and Proteins
D010455	Peptides
D001685	Biological Factors